Boston-based Beacon Biosignals, which specializes in wearable technology for brain health, announced a $97 million oversubscribed Series B funding round, totaling its funding at $132 million. Investors including JSL Health and Palo Santo VC spearheaded the latest tranche of funding, building on an initial $86 million investment from the likes of Google Ventures and General Catalyst.
“This milestone reflects strong momentum behind our vision to make brain health measurable, scalable and actionable,” Jacob Donoghue, Beacon Biosignals’ CEO, said in a statement. “We’re grateful for the support of our new and existing investors as we build the future of brain health.”
The company develops wearable solutions that leverage AI to apply precision neuroscience to clinical trials and drug development. Beacon’s solution analyzes a person’s brain activity while they sleep, allowing the device to identify biomarkers, treatment effects and patient stratification that can help researchers advance therapeutics for unmet medical needs. The company’s new injection of funding will help further this mission.
